Corporate Member Update: Merck- Keytruda® (pembrolizumab): Expanded Indication

Corporate Member Update: Merck- Keytruda® (pembrolizumab): Expanded Indication

KEYTRUDA® (pembrolizumab)
January, 2022

Merck would like to inform you that the FDA has approved KEYTRUDA® (pembrolizumab) Injection 100 mg for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB or IIC melanoma following complete resection.

To read the complete expanded indication, please click here!

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members